WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 1, 2016--
River Laboratories International, Inc. (NYSE: CRL) today launched a
full, end-to-end service offering of CRISPR/Cas9 genome engineering
technology. Through a licensing arrangement with the Broad
Institute of MIT and Harvard, Charles River can now offer custom in
vivo and in vitro genome editing. With this technology,
Charles River will be able to develop more translational research models
that will ultimately improve the efficiency and effectiveness of the
drug discovery process.
“Utilizing the CRISPR/Cas9 platform, Charles River clients can work with
a single provider for both the in vivo and in vitro phases
of their research,” said Dr. Iva Morse, Corporate Vice President, Chief
Scientific Officer, Global Research Models and Services. “Working with
us, clients can generate custom cell lines for early, exploratory
discovery research, as well as generate in vivo pharmacology
models, produce those models, and then use our Discovery Services
offering to place those models in in vivo studies.”
Charles River has developed partnerships with three key groups globally
for in vivo model creation services. In North America, the
Company is partnering with Mirimus,
a leader in RNA interference technology specializing in the creation of
customized genetically engineered mouse models. In Japan, Charles River
is partnering with the Laboratory
Animal Resource Center, University of Tsukuba, one of the country’s
largest production institutes for genetically modified mice. In Europe,
the Company is aligned with Phenomin
ICS, formerly the Institut Clinique de la Souris, a leader in mouse
and rat creation and phenotyping and a key player in different strategic
phenogenomics efforts, like the International Mouse Phenotyping
In addition to building a network of partners, Charles River has also
prepared a number of academic presentations that showcase their
CRISPR/Cas9 expertise, including:
A poster entitled Comparative Analysis of NHEJ and HDR Repair
Pathways for Genomic Editing Using CRISPR/Cas9 Technology in ES Cells
was presented at the CRISPR Genome Editing: From High-throughput
Screening to Disease Models Conference in Copenhagen.
A second poster, C57BL/6NCrl mouse models generated by
CRISPR/Cas9-mediated gene-editing, was presented at the CRISPR
Precision Genome Editing Congress Europe 2016.
David Fischer, Executive Director of Biology and DMPK spoke at the
World Preclinical Congress Europe meeting. Dr. Fischer’s presentation
on Vertical Integration of CRISPR/Cas9 Genome Engineering in
Drug Discovery detailed the numerous applications of
CRISPR/Cas9 throughout the drug discovery process by exploring
examples from Charles River case studies.
Don Liu, Senior Scientist in Charles River’s Genetically Engineered
Models and Services group, will speak at CRISPR Summit USA. Dr. Liu’s
presentation, Efficient Screening of Mutations Generated by
CRISPR/Cas9 Genome Editing, will touch on the limitations of
current post-CRISPR screening methods and present a sensitive platform
for screening CRISPR-generated mutations for in vitro and in
To learn more about Charles River’s strategic CRISPR/Cas9 initiatives,
please visit our website.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005669/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Corporate Vice President, Public Relations